Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
BIC is an integrase strand transfer inhibitor that has a higher barrier to resistance and is only used in combination. LEN has been approved as a method of pre-exposure prophylaxis but has also been ...
Zacks Investment Research on MSN
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...
In people with HIV infection aged 60 years or older, the long-acting cabotegravir and rilpivirine combination maintains high ...
Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure HIV and other ...
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Robin Lin Miller, Michigan State University (THE CONVERSATION) Protecting public ...
(THE CONVERSATION) Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do not stay within national boundaries. Increased rates of ...
Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut over ...
Zacks Investment Research on MSN
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus ...
Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback